HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Distribution Business Strategies Austria

HRA Pharma Sees Good Prospects For Austria

  • News

Executive Summary

HRA tells HBW Insight that it is seeing “a lot of growth opportunities” in the Austrian market as it takes back direct distribution of its leading consumer healthcare brands.

You may also be interested in...



South Africa Next As HRA Pharma Marches On With Global Expansion

HRA Pharma brings Compeed to South Africa, moving the company one step closer to achieving its goal of becoming a top-10 global consumer healthcare player. 

Neuraxpharm Underlines OTC Ambitions With Easypharm Acquisition

Austria's Easypharm has been snapped up by Neuraxpharm, which is looking to take a larger slice of Europe's consumer healthcare market.

HRA Pharma Taking On China With JV Partner

HRA is putting feet on the ground in China as it looks to establish itself in the world second-largest consumer health market. 

Table

View full table

Related Content

HBW Insight
HBW Insight

Topics

Related Companies

Tags:
Distribution Business Strategies Austria
Latest News

L'Oreal, Dinosaur Among The Unicorns, Talks Beauty Tech Innovation At VivaTech 2022

Nestlé Spies APAC Expansion Potential With Deal for New Zealand's Better Health

Over the Counter 29 June 2022: OTC Birth Control In The Wake Of The US Supreme Court Decision With Victoria Nichols

Proposed Rule Making More OTC Switches Likely In US Makes More Tools Necessary For Sponsors

UsernamePublicRestriction

Register

RS149665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By